Patents Assigned to Wyeth LLC
  • CCI-779 concentrate formulations
    Patent number: 8455539
    Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: June 4, 2013
    Assignee: Wyeth LLC
    Inventors: Joseph T. Rubino, Victoria Siskavich, Maureen M. Harrison, Pooja Gandhi
  • Micronized tanaproget, compositions, and methods of preparing the same
    Patent number: 8450312
    Abstract: The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, magnesium stearate, micronized edetate calcium disodium hydrous, and micronized sodium thiosulfate pentahydrate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: May 28, 2013
    Assignee: Wyeth LLC
    Inventors: Arwinder S. Nagi, Ramarao Chatlapalli, Shamim Hasan, Mohamed Ghorab, Dhaval Gaglani
  • Triazine compounds as PI3 kinase and mTOR inhibitors
    Patent number: 8445486
    Abstract: Compounds of formula I wherein: R1 is and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.
    Type: Grant
    Filed: June 6, 2012
    Date of Patent: May 21, 2013
    Assignee: Wyeth LLC
    Inventors: Aranapakam Mudumbai Venkatesan, Zecheng Chen, Christoph Martin Dehnhardt, Osvaldo Dos Santos, Efren Guillermo Delos Santos, Arie Zask, Jeroen Cunera Verheijen, Joshua Aaron Kaplan, David James Richard, Semiramis Ayral-Kaloustian, Tarek Suhayl Mansour, Ariamala Gopalsamy, Kevin Joseph Curran, Mengxiao Shi
  • Immunogenic compositions of polypeptide antigens
    Patent number: 8445000
    Abstract: The present invention relates to immunogenic compositions, comprising polypeptides isolated from Staphylococcus epidermidis. The invention also relates to polynucleotides encoding Staphylococcus epidermidis polypeptides and their use in immunogenic compostions. In addition, the invention relates to methods of inducing an immune response in mammals against Staphylococcus epidermidis and Staphylococcus aureus using immunogenic compostions of the Staphylococcus epidermidis polypeptides and polynucleotides. The invention also relates to methods for detecting Staphylococcus epidermidis in a biological sample.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: May 21, 2013
    Assignee: Wyeth LLC
    Inventors: Bret Richard Sellman, Steven Morris Baker
  • Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same
    Patent number: 8445496
    Abstract: This invention is directed to a crystalline 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile monohydrate having an x-ray diffraction pattern wherein 2? angles (°) of significant peaks are at about: 9.19, 11.48, 14.32, 19.16, 19.45, 20.46, 21.29, 22.33, 23.96, 24.95, 25.29, 25.84, 26.55, 27.61, and 29.51, and a transition temperature of about 109° C. to about 115° C.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: May 21, 2013
    Assignee: Wyeth LLC
    Inventors: Marc Sadler Tesconi, Gregg Feigelson, Henry Strong, Hong Wen
  • Methods of purifying anti A ? antibodies
    Patent number: 8440799
    Abstract: The present application provides methods of purifying A? binding proteins having a Fc region, for example, anti-A? antibodies or antibody fusions, by adsorbing the A? binding protein to a Fc binding agent, such as, for example, Protein A or Protein G, followed by a wash with a divalent cation salt buffer to remove impurities and subsequent recovery of the adsorbed A? binding protein. The present application also features methods of eluting the purified A? binding protein as well as the incorporation of the methods within a purification train. Kits comprising components for carrying out the methods and instructions for use are also provided.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: May 14, 2013
    Assignees: Janssen Alzheimer Immunotherapy, Wyeth LLC
    Inventors: Ranganathan Godavarti, Timothy Iskra
  • Burst Drug Release Compositions
    Publication number: 20130115250
    Abstract: Solid dose compositions comprising at least one low solubility pharmaceutically active ingredient, at least one low solubility filler and at least one controlled release agent. comprising at least one poorly soluble pharmaceutically active ingredient, a insoluble binder and at least one controlled release agent along with a method of manufacturing said composition are disclosed. Methods for making these compositions are also disclosed.
    Type: Application
    Filed: October 26, 2012
    Publication date: May 9, 2013
    Applicant: Wyeth LLC
    Inventor: Wyeth LLC
  • Burst Drug Release Compositions
    Publication number: 20130116327
    Abstract: A solid dose composition comprising at least one pharmaceutically active ingredient and at least one controlled release agent and method of manufacturing said composition is disclosed. The burst profile of at least one pharmaceutically active ingredient in the composition is regulated by the apparent viscosity of the controlled release agent and wherein at least one pharmaceutically active ingredient is processed by wet granulation.
    Type: Application
    Filed: October 26, 2012
    Publication date: May 9, 2013
    Applicant: Wyeth LLC
    Inventor: Wyeth LLC
  • Neutralizing antibodies against GDF-8 and uses therefor
    Patent number: 8420082
    Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: April 16, 2013
    Assignee: Wyeth LLC
    Inventors: Geertruida M. Veldman, Monique V. Davies, Kening Song, Neil M. Wolfman, Kristie Grove Bridges, Anne Field, Caroline Russell, Viia Valge-Archer
  • RATIONALLY DESIGNED MEDIA FOR CELL CULTURE
    Publication number: 20130084593
    Abstract: This invention relates to methods for rationally designing cell culture media for use in cell cultures, e.g., cell cultures employed in polypeptide production; cell culture media designed with the disclosed methods; methods of producing a polypeptide of interest, e.g., an antibody, using such media; polypeptides produced using the methods and media disclosed herein; and pharmaceuticals compositions containing such polypeptides. The rationally designed media contain a concentration of an amino acid that is calculated for use in cell mass, a concentration of the amino acid that is calculated for use in cell maintenance, and a concentration of the amino acid that is calculated for incorporation into the polypeptide of interest.
    Type: Application
    Filed: July 30, 2012
    Publication date: April 4, 2013
    Applicant: Wyeth LLC
    Inventors: Yen-Tung Luan, Wenge Wang, Ryan Nolan, Denis Drapeau
  • PET MONITORING OF A-BETA-DIRECTED IMMUNOTHERAPY
    Publication number: 20130084245
    Abstract: The present invention provides methods of monitoring A?-directed immunotherapy. The methods involve administering a PET ligand that binds to amyloid deposits and detecting the PET ligand in the brain to provide an indication of the level and/or distribution of amyloid deposits. Surprisingly, the data in the present application show that a statistically significant reduction in amyloid deposits occurs early and consistently among patients following initiation of treatment before statistically significant effects of most if not all other markers are detectable. In consequence, the present methods allow early detection of whether a patient is responding to the A?-directed immunotherapy and if necessary adjustment of the immunotherapy regime.
    Type: Application
    Filed: February 25, 2011
    Publication date: April 4, 2013
    Applicants: Wyeth LLC, Janssen Alzheimer Immunotherapy
    Inventors: Ronald Black, Michael Grundman
  • VACCINE FORMULATIONS
    Publication number: 20130072881
    Abstract: An immunogenic composition comprising a plurality of capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F conjugated to a carrier protein, and further comprising at least one preservative, preferably 2-phenoxyethanol (2-PE). The preservative-containing immunogenic compositions of the invention confer resistance to one or more micro-organisms and are useful for producing multi-dose vaccine formulations having advantageous properties with respect to long term stability of the different antigenic determinants in the immunogenic composition of choice. Related compositions and methods for measuring the efficacy of one or more preservatives in a vaccine formulation are also provided.
    Type: Application
    Filed: May 25, 2011
    Publication date: March 21, 2013
    Applicant: WYETH LLC
    Inventors: Lakshmi Khandke, Abbas Rashidbaigi
  • Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators
    Publication number: 20130072480
    Abstract: Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure: wherein R1, R2, R3, R4, R5, and Q1 are defined herein.
    Type: Application
    Filed: November 16, 2012
    Publication date: March 21, 2013
    Applicant: Wyeth LLC
    Inventor: Wyeth LLC
  • BIOMARKERS FOR PI3K-DRIVEN CANCER
    Publication number: 20130065928
    Abstract: Disclosed is the discovery that the mTORC2 complex plays a role in the regulation of PKN3 phosphorylation at the turn motif threonine; and the use of the phosphorylation status of the turn motif threonine of PKN3 as a biomarker. In some embodiments, the phosphorylation status of the turn motif threonine of PKN3 is determined using an antibody that specifically binds to the turn motif threonine of a PKN3 protein, such as an anti-phosphoT860 antibody. In some embodiments, the invention relates to methods for screening compounds that have cancer therapeutic potential, methods for diagnosing cancer, methods for determining the prognosis of a patient suffering from cancer, methods for stratifying patients in a clinical trial, methods for treating a patient suffering from cancer, and methods for determining the effectiveness of a particular treatment regimen.
    Type: Application
    Filed: April 2, 2011
    Publication date: March 14, 2013
    Applicant: WYETH LLC
    Inventors: Anke Klippel-Giese, Keziban Unsal-Kacmaz
  • Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-2-buteramide and crystalline forms thereof
    Patent number: 8394959
    Abstract: The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: March 12, 2013
    Assignee: Wyeth LLC
    Inventors: Qinghong Lu, Mannching Sherry Ku, Warren Chew, Gloria Cheal, Anthony F. Hadfield, Mahmoud Mirmehrabi
  • Tanaproget derivatives, metabolites, and uses thereof
    Patent number: 8389698
    Abstract: A method of generating synthetic metabolites of tanaproget derivatives thereof is provided. These compounds and methods of using these derivatives for detecting tanaproget metabolites in samples are provided.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: March 5, 2013
    Assignee: Wyeth LLC
    Inventors: Li Shen, Kelly Keating, Oliver McConnell, William DeMaio, Appavu Chandrasekaran
  • Processes for making hydrazides
    Patent number: 8383857
    Abstract: A method is disclosed for preparing hydrazides from hydrazine and an acyl chloride which comprises the steps of (a) preparing a stirred substantially uniform slurry comprising hydrazine and an inert solvent at low temperature; and (b) adding an acyl chloride continuously to said slurry. The method avoids or limits production of undesired bis-hydrazide by-products. The method is used to prepare 3-methyl-3-mercaptobutanoic acid hydrazide, a molecule used to link calicheamicin to a monoclonal antibody.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: February 26, 2013
    Assignee: Wyeth LLC
    Inventors: George Anello Chiarello, Ayman Sahli
  • CCI-779 CONCENTRATE FORMULATIONS
    Publication number: 20130040980
    Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.
    Type: Application
    Filed: October 15, 2012
    Publication date: February 14, 2013
    Applicant: Wyeth LLC
    Inventor: Wyeth LLC
  • Crystalline solid forms of tigecycline and methods of preparing same
    Patent number: 8372995
    Abstract: Crystalline solid forms of tigecycline, Form I, Form II, Form III, Form IV, and Form V, compositions comprising these crystalline solid forms, and processes for preparing these crystalline solid forms are described herein.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: February 12, 2013
    Assignee: Wyeth LLC
    Inventors: Lalitha Krishnan, Subodh S. Deshmukh, W. James Huang, Mannching Sherry Ku
  • Heat pack insert
    Patent number: D679823
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: April 9, 2013
    Assignee: Wyeth LLC
    Inventors: Dean Jeffrey Daniels, Karin Michele Reed